ESH 2019 | Is there a need to change AML risk stratification?

The AML Global Portal were delighted to speak to Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Eytan Stein: Is there a need to change AML risk stratification?

Eytan Stein discusses the current use of risk stratification systems promulgated by the World Health Organization (WHO) and European Leukemia Net (ELN) of stratifying patients into favorable, intermediate and unfavorable risk groups, which is determined by cytogenetics and molecular genetics at the time of diagnosis. He also explains the need to redefine risk stratification, even more, to take into account co-occurrence of mutations, as well as the need to create a robost clinically validated dynamic system.